142 related articles for article (PubMed ID: 10891115)
1. Synthesis and immunosuppressive activity of novel prodigiosin derivatives.
D'Alessio R; Bargiotti A; Carlini O; Colotta F; Ferrari M; Gnocchi P; Isetta A; Mongelli N; Motta P; Rossi A; Rossi M; Tibolla M; Vanotti E
J Med Chem; 2000 Jun; 43(13):2557-65. PubMed ID: 10891115
[TBL] [Abstract][Full Text] [Related]
2. The prodigiosins: a new family of anticancer drugs.
Montaner B; Pérez-Tomás R
Curr Cancer Drug Targets; 2003 Feb; 3(1):57-65. PubMed ID: 12570661
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, proton-affinity and anti-cancer properties of the prodigiosin-group natural products.
Manderville RA
Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):195-218. PubMed ID: 12678767
[TBL] [Abstract][Full Text] [Related]
4. New insights on the antitumoral properties of prodiginines.
Pérez-Tomás R; Viñas M
Curr Med Chem; 2010; 17(21):2222-31. PubMed ID: 20459382
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.
Yoshimura H; Kikuchi K; Hibi S; Tagami K; Satoh T; Yamauchi T; Ishibahi A; Tai K; Hida T; Tokuhara N; Nagai M
J Med Chem; 2000 Jul; 43(15):2929-37. PubMed ID: 10956201
[TBL] [Abstract][Full Text] [Related]
6. Indoloprodigiosins from the C-10 bipyrrolic precursor: new antiproliferative prodigiosin analogs.
Baldino CM; Parr J; Wilson CJ; Ng SC; Yohannes D; Wasserman HH
Bioorg Med Chem Lett; 2006 Feb; 16(3):701-4. PubMed ID: 16289814
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulating properties of prodigiosin 25-C, an antibiotic which preferentially suppresses induction of cytotoxic T cells.
Tsuji RF; Magae J; Yamashita M; Nagai K; Yamasaki M
J Antibiot (Tokyo); 1992 Aug; 45(8):1295-302. PubMed ID: 1399851
[TBL] [Abstract][Full Text] [Related]
8. Chemistry and biology of roseophilin and the prodigiosin alkaloids: a survey of the last 2500 years.
Fürstner A
Angew Chem Int Ed Engl; 2003 Aug; 42(31):3582-603. PubMed ID: 12916029
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase 3: a novel target for selective transplant immunosupression.
Podder H; Kahan BD
Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
[TBL] [Abstract][Full Text] [Related]
10. Role of interleukin-2 regulated proteins in immunosuppression by the N-alkylated prodigiosin analogue.
Pandey R; Chander R; Sainis KB
Int Immunopharmacol; 2007 Dec; 7(13):1695-703. PubMed ID: 17996679
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of nonylprodigiosin and macrocyclic prodigiosin analogues.
Fürstner A; Grabowski J; Lehmann CW; Kataoka T; Nagai K
Chembiochem; 2001 Jan; 2(1):60-8. PubMed ID: 11828428
[TBL] [Abstract][Full Text] [Related]
12. Selective suppression by prodigiosin of the mitogenic response of murine splenocytes.
Nakamura A; Nagai K; Ando K; Tamura G
J Antibiot (Tokyo); 1986 Aug; 39(8):1155-9. PubMed ID: 2944863
[TBL] [Abstract][Full Text] [Related]
13. The prodigiosins, proapoptotic drugs with anticancer properties.
Pérez-Tomás R; Montaner B; Llagostera E; Soto-Cerrato V
Biochem Pharmacol; 2003 Oct; 66(8):1447-52. PubMed ID: 14555220
[TBL] [Abstract][Full Text] [Related]
14. A novel prodigiosin-like immunosuppressant from an alkalophilic Micrococcus sp.
Pandey R; Chander R; Sainis KB
Int Immunopharmacol; 2003 Feb; 3(2):159-67. PubMed ID: 12586597
[TBL] [Abstract][Full Text] [Related]
15. Equilibrium and kinetics of rotamer interconversion in immunosuppressant prodigiosin derivatives in solution.
Rizzo V; Morelli A; Pinciroli V; Sciangula D; D'Alessio R
J Pharm Sci; 1999 Jan; 88(1):73-8. PubMed ID: 9874705
[TBL] [Abstract][Full Text] [Related]
16. Investigations regarding the utility of prodigiosenes to treat leukemia.
Smithen DA; Forrester AM; Corkery DP; Dellaire G; Colpitts J; McFarland SA; Berman JN; Thompson A
Org Biomol Chem; 2013 Jan; 11(1):62-8. PubMed ID: 23070266
[TBL] [Abstract][Full Text] [Related]
17. Prodigiosin 25-C suppression of cytotoxic T cells in vitro and in vivo similar to that of concanamycin B, a specific inhibitor of vacuolar type H(+)-ATPase.
Lee MH; Kataoka T; Magae J; Nagai K
Biosci Biotechnol Biochem; 1995 Aug; 59(8):1417-21. PubMed ID: 7549091
[TBL] [Abstract][Full Text] [Related]
18. Influence of the a-ring on the redox and nuclease properties of the prodigiosins: importance of the bipyrrole moiety in oxidative DNA cleavage.
Melvin MS; Calcutt MW; Noftle RE; Manderville RA
Chem Res Toxicol; 2002 May; 15(5):742-8. PubMed ID: 12018997
[TBL] [Abstract][Full Text] [Related]
19. Tautomeric equilibria in phenolic A-ring derivatives of prodigiosin natural products.
La JQ; Michaelides AA; Manderville RA
J Phys Chem B; 2007 Oct; 111(40):11803-11. PubMed ID: 17867672
[TBL] [Abstract][Full Text] [Related]
20. Identification of a prodigiosin cyclization gene in the roseophilin producer and production of a new cyclized prodigiosin in a heterologous host.
Kimata S; Izawa M; Kawasaki T; Hayakawa Y
J Antibiot (Tokyo); 2017 Feb; 70(2):196-199. PubMed ID: 27460763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
